



IBA Signs Contract with UZ Leuven to Install the First Proton Therapy Center in Belgium

Louvain-la-Neuve, Belgium, March 25, 2016 - IBA ([Ion Beam Applications SA](#)), the world's leading provider of proton therapy solutions for the treatment of cancer, announces today that it has signed a contract with the University Hospitals Leuven (UZ Leuven) and Katholieke Universiteit Leuven (KU Leuven) to install Belgium's first proton therapy center in a project with Université Catholique de Louvain (UCL), Cliniques universitaires Saint-Luc and other Belgian universities. IBA was awarded the contract following a comprehensive European public tender conducted by UZ Leuven.

IBA will equip the new center with its *Proteus[®]ONE** system. The contract will also include a long-term maintenance agreement. The typical end-user price for a *Proteus[®]ONE* system with such a maintenance contract is between EUR 35 and 40 million. This new center is expected to open in 2018.

Olivier Legrain, Chief Executive Officer of IBA commented: *"We are excited to have been selected to install Belgium's first proton therapy center, bringing access to the most advanced radiation therapy technology to Belgian cancer patients. We are proud to install our cutting edge Proteus[®]ONE system so close to our headquarters and we look forward to collaborating with leading institutions like UZ Leuven, KU Leuven, UCL, Saint-Luc, and the other Belgian universities involved in the project."*

Marc Decramer, Chief Executive Officer of UZ Leuven commented: *"We are very pleased to announce that we will be working with IBA. The UZ Leuven mission is to deliver the highest quality and most innovative patient care with unrelenting attention to clinical excellence, patient care and patient safety. It was therefore a natural decision for us to equip our hospital with a proton therapy solution as it is the most targeted treatment in the fight against cancer. Following a comprehensive public tender, we have chosen IBA because it provided the proton therapy solution that best fitted our needs."*

- ENDS -

Notes to Editors

About Proton Therapy

Proton Therapy is considered the most advanced and targeted cancer treatment due to its superior dose distribution and fewer side effects. Protons deposit the majority of their effective energy within a precisely controlled range, directly within the tumor, sparing healthy surrounding tissue. Higher doses



can be delivered to the tumor without increasing the risk of side effects and long-term complications, thereby improving patient outcomes and quality of life.

Today, more than half of all proton therapy clinical facilities worldwide are equipped with IBA systems. This includes 22 proton therapy centers currently in operation and 18 additional centers under development. Over 50,000 patients have been treated with IBA equipment, which is more than all major competitive installations combined.

About Proteus®ONE

Proteus®ONE comprises the latest technologies in proton therapy, which makes it the ideal platform for research and development purposes. Proteus®ONE is smaller, more affordable, easier to install, operate and ultimately finance. All these advantages make this therapy solution accessible to more and more healthcare institutions worldwide. Proteus®ONE is equipped with Pencil Beam Scanning, a technology that offers a millimeter precision treatment, delivered with very high levels of conformity and dose uniformity, even in complex-shaped tumors, whilst at the same time sparing the surrounding healthy tissue.

**Proteus®ONE is the brand name of a new configuration of the Proteus® 235*

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The Company is the worldwide technology leader in the field of proton therapy, the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.

Headquartered in Belgium and employing about 1200 people worldwide, IBA has installed systems across the world, from Europe and the US and to the emerging markets. IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

About UZ Leuven

There are 1,955 beds in the University Hospitals Leuven, making it the largest university hospital in Belgium. Every day, more than 9,000 enthusiastic employees do their utmost to provide diverse and specialist patient care and work continuously on improving and updating that care. The University Hospitals Leuven's strength lies in combining top quality patient care, excellent innovative scientific research and high-standing academic training. It was also the first Belgian hospital to acquire the international JCI label for safe and quality care. More information can be found at: www.uzleuven.be



For further information please contact:

IBA

Jean-Marc Bothy
Chief Financial Officer
+32 10 475 890

Investorrelations@iba-group.com

Thomas Ralet
Vice-President Corporate Communication
+32 10 475 890

Communication@iba-group.com

Contact UZ Leuven

Communication Department:
+32 16 34 49 55 or +32 16 34 49 85

communicatie@uzleuven.be

For media and investor enquiries:

Consilium Strategic Communications

Amber Fennell, Matthew Neal, Ivar Milligan
+44 (0) 20 3709 5700

IBA@consilium-comms.com

Rx Communications Group (US)

Melody Carey
+ 1 917 322 2571

mcarey@RxIR.com